[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"higher-risk-myelodysplastic-syndromes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:higher-risk-myelodysplastic-syndromes":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,86,110,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100644648","phase-2-bexmarilimab--azacitidine-versus-placebo--azacitidine-in-participants-with-treatment-nave-higher-risk-myelodysplastic-syndromes-100644648",false,"NCT07672769","Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes","Bexmarilimab Plus Azacitidine in a Randomized, Double-blind, Placebo-controlled Phase IIb Trial in Treatment-naïve Higher-risk Myelodysplastic Syndromes (HR-MDS)","BEXERA","Inclusion Criteria:\n\n1. Participant provides written informed consent.\n2. Participant is ≥18 years of age.\n3. Participant has newly diagnosed MDS with morphologically confirmed HR-MDS as defined according to 2022 World Health Organization classification (5th Edition, Annex 7).\n\n   1. IPSS-M classification of moderately high risk, high risk, and very high risk.\n   2. \\\u003C20% bone marrow blasts per bone marrow biopsy\u002Faspirate at screening\n4. Participant is eligible for azacitidine per local practice and willing to initiate trial therapy.\n5. Participant has ECOG performance score 0 to 2.\n6. Participant has life expectancy ≥3 months.\n7. Participant has adequate organ function: creatinine clearance ≥30 mL\u002Fmin (Cockcroft-Gault); indirect (unconjugated) bilirubin ≤1.5 times the upper limit of normal (ULN) (unless related to Gilbert's syndrome, in which case the indirect bilirubin levels must be \\\u003C3×ULN for inclusion); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3×ULN.\n8. Participant has baseline leukocyte count of \\\u003C20×109\u002FL. Hydroxycarbamide use is permitted to meet this criterion.\n9. Women of childbearing potential have a negative pregnancy test; participants of childbearing potential (and their partners) agree to use highly effective contraception during treatment and for ≥6 months after last dose.\n10. Participant is willing and able to comply with protocol procedures and follow up.\n\nExclusion Criteria:\n\n1. Participant has a previous diagnosis of AML, has transformed to AML, or has MDS subtypes outside the scope or overlapping myeloid neoplasms: MDS evolved from pre-existing myeloproliferative neoplasms (MPN); MDS\u002FMPN overlap (e.g., chronic myelomonocytic leukemia, acute chronic myeloid leukemia, juvenile myelomonocytic leukemia, unclassifiable); advanced myelofibrosis (MF Grade ≥3); or severe autoimmune hemolysis.\n2. Participants who are considered appropriate candidates for immediate allogeneic haematopoietic stem cell transplantation (HSCT) at the time of screening are excluded, irrespective of transplant timing, donor availability, or planned bridging therapy. Determination of transplant candidacy should be based on institutional standards and routine clinical practice, including assessment of individual clinical factors such as age, performance status, comorbidities, organ function, disease risk, and donor suitability.\n3. Participants with ≥20% blasts in peripheral blood or bone marrow or evidence of myeloid sarcoma (extramedullary AML).\n4. Participant has a lack of screening cytogenetic data or demonstrated normal karyotype per local or central analysis, should the patient have \\\u003C5% blasts at screening.\n5. Participant has received previous lines of anticancer therapy for MDS (disease-modifying therapy), including HMAs (e.g., azacitidine, decitabine), chemotherapy, or HSCT. Supportive care (e.g., transfusions, growth factors) is permitted.\n6. Participant has clinically significant cardiac disease: recent myocardial infarction within 12 months; symptomatic congestive heart failure (New York Heart Association Class III or IV) or left ventricular ejection fraction (LVEF) \\\u003C40%; uncontrolled clinically significant arrhythmias; or congenital\u002Ffamilial long-QT syndrome or pre-excitation syndrome.\n7. Participant has active, uncontrolled infection requiring IV antimicrobials; known active invasive fungal infection; uncontrolled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection per local standards.\n8. Participant has known active central nervous system (CNS) involvement by myeloid malignancy\n9. All prior allo-HSCT within 6 months before Screening; ongoing clinically significant graft versus host disease (GVHD) requiring systemic immunosuppression.\n10. Participant has active autoimmune disease requiring systemic therapy or requiring ≥10 mg\u002Fday prednisone (or equivalent) within 14 days prior to first dose; topical\u002Finhaled\u002Fophthalmic steroids permitted. (Immune conditions such as type 1 diabetes, controlled thyroid disease, vitiligo, psoriasis, alopecia are not exclusions.)\n11. Participant has clinically relevant hepatic disease (e.g., Child-Pugh C) or ALT\u002FAST \\>3×ULN and bilirubin exceeding inclusion thresholds (indirect \\[unconjugated\\] bilirubin \\>1.5×ULN \\[unless related to Gilbert's syndrome, in which case the indirect bilirubin levels must be \\>3×ULN\\]); persistent chronic ulcers with high risk of infection per investigator's assessment.\n12. Participant has received recent non-MDS related anticancer therapy or investigational agents within drug-specified washout periods (e.g., \\\u003C21 days from last IV\u002FSC cytotoxic, \\\u003C14 days or \\\u003C5 half-lives for small-molecule therapy, \\\u003C4 weeks for other immunotherapies).\n13. Participant has a history of another malignancy that is active, progressing, or has required systemic treatment within the past 2 years of screening, excluding non-melanoma skin cancer, carcinoma in situ treated with curative intent.\n14. Participant has known uncontrolled human immunodeficiency virus, active hepatitis B virus, or hepatitis C virus with high-level viremia; participants with controlled viral infections on stable therapy may be eligible per local guidance.\n15. Participant is pregnant or lactating.\n16. Participant has prior exposure to bexmarilimab.\n17. Participant has any condition, including psychiatric or substance-use disorder, that in the investigator's judgment would compromise informed consent, compliance, or interpretation of trial results.\n18. Participant has a history of hypersensitivity to compounds related to immunotherapy or to any of their excipients.\n19. Participant has undergone major surgery within 4 weeks of Cycle 1 Day 1.","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This Phase IIb study (BEXERA) will evaluate the safety and efficacy of bexmarilimab (FP-1305), an antibody targeting Clever-1, given in combination with azacitidine compared with azacitidine plus placebo in adults with treatment-naïve higher-risk myelodysplastic syndromes (HR-MDS). Participants will be randomized to receive bexmarilimab at one of two dose levels (1 mg\u002Fkg or 3 mg\u002Fkg) plus azacitidine, or placebo plus azacitidine. The primary aim is to select the recommended dose of bexmarilimab for subsequent development based on a predefined integration of clinical response and safety\u002Ftolerability.",[27],"Higher Risk Myelodysplastic Syndromes",[29,30,31,32,33,34,35,36,37,38],"higher risk myelodysplastic syndromes","HR-MDS","Bexmarilimab","Hematoligical","Malignancies","Immunotherapy","CLEVER-1","anti-CLEVER-1","MDS","azacitidine","NOT_YET_RECRUITING","2026-06-22",{"date":42,"type":43},"2026-06-29","ACTUAL",{"date":45,"type":21},"2026-10-01",{"date":47,"type":21},"2030-12-31",{"name":49,"class":50},"Faron Pharmaceuticals Ltd","INDUSTRY",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100604877","phase-1-study-of-azd3632-monotherapy-or-in-combination-with-anticancer-agents-in-participants-with-advanced-haematologic-malignancies-with-kmt2ar-npm1m-or-other-genotypes-associated-with-hox-overexpression-100604877","NCT07155226","Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","A Modular Phase I\u002FII, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","MOMENTUM","Key Inclusion Criteria:\n\nCore criteria:\n\n* Adequate organ function.\n* Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nModule 1:\n\n* Advanced haematologic malignancy - a) for dose escalation - diagnosis of acute leukemia or myelodysplastic neoplasia (MDS) and harbouring one of the genetic alterations per local testing associated with upregulation of HOX; b) for Backfill - diagnosis of harbouring a KMT2Ar or NPM1m per local testing.\n* Participants must have measurable disease that is relapsed\u002Frefractory to conventional therapies known to be effective for their disease and not have any available approved therapies.: a) Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, hypomethylating agent (HMA) monotherapy, or HMA combinations such as HMA\u002Fvenetoclax.; b) Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and\u002For persistence of peripheral blasts after treatment with at least 2 cycles of HMA. Participants ineligible for the treatment with an HMA and without any other standard of care (SoC) options are allowed to enrol; c) White blood cell count below 25,000\u002FμL. Participants may receive cytoreduction per protocol-specified criteria; d) Performance status: Eastern Cooperative Operative Group (ECOG) ≤ 2; e) Life expectancy: ≥ 8 weeks.\n\nModule 2:\n\n* Participants must have measurable disease that is relapsed\u002Frefractory to conventional therapies known to be effective for their disease and not have any available approved therapies.: a) Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, HMA monotherapy, or HMA combinations such as HMA\u002Fvenetoclax.; b) Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and\u002For persistence of peripheral blasts after treatment with at least 2 cycles of HMA. Participants ineligible for the treatment with an HMA and without any other SoC options are allowed to enrol; c) White blood cell count below 25,000\u002FμL. Participants may receive cytoreduction per protocol-specified criteria; d) Performance status: ECOG ≤ 2; e) Life expectancy: ≥ 8 weeks.\n\nKey Exclusion Criteria:\n\nCore criteria:\n\n* Participants with Burkitt lymphoma\u002Fleukaemia or Acute Promyelocytic Leukaemia.\n* Active testicular or active central nervous system (CNS) (\\> CNS1 or radiographic) involvement by leukaemia.\n* Unresolved treatment-related toxicities Grade ≥ 2 from prior therapy.\n* Abnormal levels of potassium or magnesium prior to first dose of AZD3632.\n\nModule 1:\n\n* Receipt of non-CNS radiation therapy within 2 weeks and of CNS radiation within 8 weeks of the first scheduled dose.\n* Receipt of any investigational or non-investigational anticancer agents, including non-biologic agents, biologic agents and\u002For prior treatment other menin inhibitors (backfill participants only).\n* For nested food effect participants - diagnosis of diabetes mellitus (Type I or Type II).\n\nModule 2:\n\n* Receipt of any non-investigational anticancer agents, including non-biologic agents and\u002For biologic agents or receipt of non-CNS or CNS radiation therapy.\n* Participants for whom treatment with posaconazole is contraindicated per the local prescribing information.","16 Years",{"count":61,"type":21},84,[63,24],"PHASE1","The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.",[66,67,68],"Acute Lymphoblastic Leukaemia","Acute Myeloid Leukaemia","Higher-risk Myelodysplastic Syndromes",[70,71,72,73,74],"Myelodysplastic Syndromes","Menin inhibitor","Anti-leukaemic activity","Anti-fungal agent","HOX overexpression.","RECRUITING","2026-06-16",{"date":78,"type":43},"2026-06-17",{"date":80,"type":43},"2026-01-09",{"date":82,"type":21},"2029-02-15",{"name":84,"class":50},"AstraZeneca",30,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100538984","phase-1-study-of-rem-422-in-patients-with-aml-or-higher-risk-mds-100538984","NCT06297941","Study of REM-422 in Patients With AML or Higher Risk MDS","A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed\u002FRefractory AML or Higher-Risk MDS","Inclusion Criteria:\n\n1. Be able to provide informed consent.\n2. Be 18 or older at the time of informed consent.\n3. Disease criteria:\n\n   Histologically confirmed diagnosis of either:\n   1. R\u002FR AML, defined as relapse after transplantation, second or later relapse, refractory to initial induction or reinduction treatment or to initial treatment with hypomethylating (HMA)-based combinations, relapse after initial treatment, or otherwise considered relapsed or refractory in the opinion of the Investigator.\n   2. High-risk and very-high-risk (VHR) MDS (higher-risk) per the International Prognostic Scoring System-Revised (IPSS-R) and\u002For International Prognostic Scoring System-Molecular (IPSS-M).\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. Has agreed to undergo serial blood and bone marrow sampling.\n6. Participants must have completed systemic non-investigational therapy at least 14 days prior to initiating REM-422. Hydroxyurea is permissible for controlling peripheral leukemic blasts prior to enrollment and for up to 28 days following initiation of REM-422.\n7. Toxicities from prior therapy must be either stable or recovered to ≤ Grade 1.\n8. Participants must be able to swallow and retain oral medications.\n9. Oxygen saturation \\> 92% on room air or up to 2 L\u002Fmin supplemental oxygen by nasal cannula with ≤ Grade 1 dyspnea.\n10. People of childbearing potential (POCBP) must have a negative serum beta-human chorionic gonadotropin test result.\n11. POCBP must agree to use acceptable, effective methods of contraception and not donate ova from screening until 6 months after discontinuation of REM-422. Women who have undergone surgical or ablative sterilization or who have been postmenopausal for ≥ 2 years are not considered to be of childbearing potential.\n12. Men must agree to use acceptable, effective methods of contraception and must agree not to donate sperm from the start of receiving REM-422 until 6 months after discontinuation of REM-422.\n13. Adequate organ function and laboratory parameters\n\nExclusion Criteria:\n\n1. Active central nervous system (CNS) leukemia or a confirmed diagnosis of CNS leukemia.\n2. Has undergone hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of REM-422 or is receiving immunosuppressive therapy post HSCT at the time of screening, or has GVHD requiring systemic treatment (topical steroids for ongoing skin GVHD is permitted).\n3. Has immediate, life-threatening, severe complications of leukemia, such as uncontrolled bleeding, pneumonia with hypoxia or sepsis, and\u002For disseminated intravascular coagulation.\n4. Known hypersensitivity or contraindication to any component of REM-422 or to drugs chemically related to REM-422 or its excipients.\n5. Clinically significant active infection. Note: Patients with simple urinary tract infection or uncomplicated bacterial pharyngitis responding to active treatment are permitted. Note: Patients receiving intravenous (IV) antibiotics ≤ 7 days prior to enrollment are excluded (prophylactic antibiotics, antivirals, or antifungals are permitted).\n6. Evidence of active HIV infection.\n7. Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n8. Primary immunodeficiency.\n9. Current or expected need for daily systemic corticosteroid therapy ≥ 10 mg of prednisone equivalent.\n\n   Note: Patients who are receiving topical or inhaled corticosteroids with minimal systemic absorption are eligible for enrollment and may continue with minimal corticosteroid use as long as they are on a stable dose.\n10. Live vaccine ≤ 6 weeks prior to the start of REM-422.\n11. Use of strong CYP3A inhibitors (except azole antifungals) or CYP3A inducers\n12. Drugs that reduce gastric acidity, such as H2-receptor antagonists (eg, ranitidine, famotidine) and proton pump inhibitors (eg, omeprazole, esomeprazole) within 7 days prior to the initiation of REM-422 administration or during the study.\n13. Currently pregnant, have intentions to become pregnant during the study duration, or are currently lactating.\n14. Has dysphagia, short-gut syndrome, gastroparesis, or any other condition that limits the ingestion or gastrointestinal absorption of orally administered drugs.\n15. Current use of prohibited medication ≤ 1 week before starting REM-422.\n16. Clinically significant cardiovascular disease:\n17. Has undergone major surgery (opening a mesenchymal barrier such as the pleural cavity, peritoneum, or meninges or surgical procedures requiring general anesthesia) \\\u003C 4 weeks prior to enrollment.\n18. History of organ transplant that requires use of immunosuppressive agents.\n19. History or current autoimmune disease requiring systemic treatment (eg, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus).\n20. Radiation therapy ≤ 7 days prior to the start of REM-422.\n21. Concurrent or previous other malignancy ≤ 2 years of enrollment, except curatively treated malignancies including basal or squamous cell skin cancer, breast cancer, prostate intraepithelial neoplasm, and carcinoma in situ of the cervix.\n22. Receiving any other investigational treatment for any indication ≤ 3 weeks prior to enrollment.\n23. Unwillingness or inability to follow protocol requirements.\n24. Any condition that, in the opinion of the Investigator, would interfere with evaluation of REM-422 or interpretation of the participant's safety or study results.",{"count":94,"type":21},100,[63],"The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed\u002Frefractory AML",[70,27,98,99],"Acute Myeloid Leukemia","Acute Myeloid Leukemia Refractory","2025-04-18",{"date":102,"type":43},"2025-04-23",{"date":104,"type":43},"2024-04-26",{"date":106,"type":21},"2027-06-15",{"name":108,"class":50},"Remix Therapeutics",9,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100531162","phase-2-a-study-of-ak117-in-combination-with-azacitidine-in-patients-with-myelodysplastic-syndromes-100531162","NCT06196203","A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes","A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117\u002FPlacebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes","Inclusion Criteria:\n\n* Age ≥ 18 years old at the time of enrolment.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.\n* Expected life expectancy ≥ 3 months.\n* Newly diagnosed HR-MDS, according to the 2016 World Health Organization (WHO) classification with the presence of \\\u003C 20% blasts in bone marrow or peripheral blood; Overall IPSS-R score ≥ 3.5.\n* Ability to undergo the study-required bone marrow sample collection procedures.\n* Suitable venous access for the study-required blood sampling (i.e., including PK and immunogenicity).\n* Female patients of childbearing age must have negative serum pregnancy test results before randomization or per region-specific guidance documented in the informed consent and a negative urine pregnancy test on the day of first dose prior to dosing.\n* Female patients of childbearing potential having sex with an unsterilized male partner must agree to use a highly effective method of contraception from the beginning of screening until 180 days after the last dose of the study treatment.\n* Unsterilized male patients having sex with a female partner of childbearing potential must agree to use an effective method of contraception from the beginning of screening until 180 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* MDS evolving from a pre-existing myeloproliferative neoplasm (MPN), myelodysplastic\u002Fmyeloproliferative neoplasms (MDS\u002FMPN).\n* Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents.\n* Concurrently participating in another interventional clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.\n* Patients who previously diagnosed with another malignancy and have any evidence of residual disease.\n* Known allergy to any component of any study drug; known history of severe hypersensitivity to other monoclonal antibodies.\n* Patients with any psychiatric or social factor which the investigator deems may interfere with the patient's ability to comply with the requirements of the study.\n* Patients with current hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy.\n* Patients with known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV), decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders.\n* Patients who are breastfeeding or plans to breastfeed during the study.\n* Other conditions where the investigator considers the patient inappropriate for enrollment.",{"count":20,"type":21},[24],"This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).",[68],"2025-02-09",{"date":123,"type":43},"2025-02-11",{"date":125,"type":43},"2024-02-07",{"date":127,"type":21},"2026-06",{"name":129,"class":50},"Akeso",15,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100552350","phase-1-va-conditioning-regimen-allo-hsct-for-elderly-higher-risk-mds-100552350","NCT06471946","VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS","Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes","Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO).\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.","70 Years",{"count":140,"type":21},54,[63,24],"The goal of this phase 1\u002F2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.",[68],"2024-09-28",{"date":146,"type":43},"2024-10-01",{"date":146,"type":21},{"date":149,"type":21},"2030-09-01",{"name":151,"class":152},"Navy General Hospital, Beijing","OTHER",1]